PROSTOX Standard targets CFRT (37–45 fractions) and MHFRT (20–28 fractions), expanding a regimen-specific platform aimed at predicting late GU toxicity after EBRT in localized prostate cancer.

Austin Kirschner, MD, PhD, discusses the recent US commercial launch of the PROSTOX Standard test and its potential to inform radiation treatment decisions for patients with prostate cancer. In the ...

Oncologists discuss the importance of guidelines like NCCN and ASCO for navigating cancer treatment complexities and insurance challenges. What recent guideline updates or data have most influenced ...

Ezra J. Margolin, MD, highlights a recent study examining antibiotic prescribing patterns for patients presenting to the emergency department with kidney stones. In the following video, Ezra J.

In this episode, Amy Pearlman, MD, sits down with Alan J. Wein, MD, PhD (hon), FACS, to discuss how the field of urology has evolved and how clinicians can thoughtfully evolve alongside it. In this ...

Apalutamide significantly improves overall survival in patients with mCSPC compared with darolutamide without concurrent docetaxel, showing a 51% reduction in death risk at 24 months. The real-world ...

The conversation explores the growing role of at-home semen testing kits as screening tools, their advantages in accessibility and privacy, and their limitations compared with in-lab testing. In this ...

Natera seeks FDA approval for Signatera CDx as a companion diagnostic for MIBC, guiding atezolizumab treatment. Phase 3 IMvigor011 trial data supports the application, showing ctDNA's predictive value ...

Experts discuss the complexities of advanced imaging in cancer diagnosis, highlighting challenges with PET scans and the importance of accurate interpretation. This episode, titled ‘InterpretingPSMA ...

The EMA's CHMP recommends expanding niraparib and abiraterone acetate use for mHSPC patients with BRCA1/2 mutations, based on phase 3 AMPLITUDE trial results. The AMPLITUDE trial showed significant ...

A negative PSMA-PET/CT at BCR identified a favorable-risk group with 2- and 5-year PFS of 78.3% and 62.4%, respectively, despite no visible lesions. Whole-pelvis radiotherapy improved PFS in locally ...